Revectina for rosacea
- Revectina 1% topical cream is used to treat lesions of rosacea. Rosacea is a skin disease that causes redness and pimples on your nose, cheeks, chin, and forehead.
To use Soolantra™ topical cream:
- This medicine is for use on the skin only. Do not get it in your eyes, mouth, or vagina. Do not use it on skin areas that have cuts or scrapes. If it does get on these areas, rinse it off right away.
- Wash your hands before and after using this medicine.
- Use a pea-sized amount for each affected area of the face (forehead, chin, nose, cheeks).
- Spread a thin layer and avoid the eyes and lips.
For patients using Soolantra™:
- If your skin problem does not improve within a few days or if it becomes worse, check with your doctor.
- Do not use this medicine for a skin problem that has not been checked by your doctor.
- If you have any questions about this, check with your doctor.
Cutaneous, systemic and/or ophthalmological reactions have been reported with other microfilaricidal drugs. Allergic and inflammatory reactions (the Mazzotti reaction) may occur with Revectina, probably due to the death of the microfilariae. Patients treated with Revectina therapy for onchocerciasis may experience these reactions in addition to clinical adverse reactions possibly, probably, or definitely related to the therapy itself. The treatment of severe Mazzotti reactions has not been subjected to controlled clinical studies. Oral or intravenous rehydration, corticosteroids, antihistamines, acetaminophen and/or aspirin have been used for treatment.
After treatment with microfilaricidal medications, patients with hyperreactive onchodermatitis (sowda) may be more likely than others to experience severe adverse reactions, especially edema and aggravation of onchodermatitis.
Serious or fatal encephalopathy has been reported rarely in patients with onchocerciasis, and heavily infected with Loa loa, either spontaneously or after treatment with Revectina. In these patients, pain (including neck and back pain), red eye, conjunctival hemorrhage, dyspnea, urinary and/or fecal incontinence, difficulty in standing/walking, mental status changes, confusion, lethargy, stupor, seizures, or coma have been reported. This syndrome has been seen very rarely following the use of Revectina therapy. Pretreatment assessment for loiasis and careful posttreatment follow-up should be implemented in all patients considered for treatment with Revectina for any reason and who had exposure to Loa loa endemic areas of West and Central Africa.
The patient should be advised of the need for repeated stool examinations to document clearance of infection with Strongyloides stercoralis.
The patient should be advised that treatment with Revectina does not kill the adult Onchocerca parasites, and therefore repeated follow-up and retreatment is usually necessary.
In immunocompromised (including HIV-infected) patients being treated for intestinal strongyloidiasis, repeated courses of therapy may be necessary. Adequate and well-controlled clinical trials have not been conducted in such patients to determine the optimal dosing regimen. Several treatments, i.e., at 2-week intervals, may be required, and cure may not be attained. Control of extraintestinal strongyloidiasis in these patients is difficult, and suppressive therapy, i.e., once per month, may be useful.
Revectina is extensively metabolized in the liver and should be used cautiously in patients with hepatic disease. Dosage adjustments may be needed, although specific recommendations are not currently available. The manufacturer does not recommend that Revectina treatment be excluded in patients with liver disease.
Clinical trials of Revectina did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, treatment of elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Safety and effectiveness in pediatric patients weighing less than 15 kg have not been determined.
Revectina is approved for use in many animals, including cattle, sheep, horses, pigs, dogs, and cats. Similar to human use, Revectina acts as an antiparasitic agent in the treatment of worms and arthropods, including :
- Heartworm (Dirofilaria immitis)
- Intestinal roundworms
- Mange mites
- Ticks – specifically Boophilus sp.
- Biting flies
Revectina side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
eye pain or redness, puffy eyes, problems with your vision;
severe skin rash, itching, or rash with pus;
confusion, change in your mental status, balance problems, trouble walking;
fever, swollen glands, stomach pain, joint pain, swelling in your hands or feet;
loss of bladder or bowel control;
neck or back pain, seizure (convulsions); or
a light-headed feeling, like you might pass out.
Common side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
STROMECTOL (Revectina) is excreted in human milk in low concentrations. Treatment of mothers who intend to breastfeed should only be undertaken when the risk of delayed treatment to the mother outweighs the possible risk to the newborn.
Side effects of Revectina
Side effects of oral Revectina are rare and usually minor. These include:
- Transient tachycardia (fast heart rate)
- In treatment of onchocerciasis; fever , rash , muscle or joint aches and tender glands and eye irritation/swelling or pain
- In treatment of strongylo >neurological side effects are theoretically possible in rare susceptible individuals
The safety of Revectina in pregnant women has not been studied and such use is not recommended. Studies in animals have shown an increase in birth defects. Safety and effectiveness in children under 15kg has not been established. Revectina passes into breast milk and use during breast feeding is not recommended.
Revectina cream can irritate and cause a burning sensation on treated skin.
Uses of Revectina (Stromectol) + Dosage & S > Written by Mathew Eng, PharmD | Reviewed by Ana Aleksic, MSc (Pharmacy), Biljana Novkovic, PhD | Last updated: November 28, 2019
Why it's used
Revectina oral tablet is used to treat infections of parasites. These include parasitic infections of your intestinal tract, skin, and eyes.